7,018,987, titled "Synthesis of Combretastatin A4 Prodrugs and Trans-Isomers Thereof," which covers methods of synthesizing its lead drug candidate, CA4P

That patent covers methods of using the reovirus ex vivo to eliminate contaminating cancer cells from autologous blood stem cell transplants

It covers a method for the synthesis of aminosterol compounds, such as Evizon, squalamine for cancer and trodusquemine

This patent, licensed exclusively from the Mayo Clinic, covers methods of using selective amyloid beta 42 lowering agents

6,828,091, titled "Method of Identifying Immunosuppressive Agents," which covers a method for identifying agents by screening for compounds that induce apoptosis in activated T or B cells

The patent covers methods of modeling biological processes in the joint, including cartilage metabolism and tissue inflammation

The patent covers a method of producing neural cells by culturing hESCs in the presence of a mitogen and a neurotrophin

It covers a method comprising the use of adhesive tape to recover ribonucleic acid from the surface of the skin

patent that covers the method of using bases to enhance the permeation of amine drugs across the skin

6,737,064 titled "Method for the Diagnosis of Neoplastic Tissue Comprising Administering a Vasopermeability Enhancing Peptide of Human Interleukin-2," which covers methods for using the permeability-enhancing peptide portion of interleukin-2 to enhance the diagnosis of cancer

6,706,484, which covers the method of obtaining an antigen-specific antibody or an antibody fragment from the HuCAL (Human Combinatorial Antibody Library

The patent also covers methods to prepare the vaccine...6,524,583 titled "Antibody Methods for Selectively Inhibiting VEGF," which covers methods for treating a variety of angiogenesis-dependent diseases

6,642,048, which includes claims that cover methods and compositions for growing human embryonic stem cells using cell-free conditioned media

The patent, which will remain in force until 2020, also covers a method of treating multiple sclerosis, systemic lupus erythematosis and scleroderma with CTLA4-Ig and the use of CTLA4-Ig in combination with other immunosuppressants...More specific claims cover methods for stable gene delivery to lymphocytes, dendritic cells and hematopoietic stem cells

The patent, which will remain in force until 2020, also covers a method of treating multiple sclerosis, systemic lupus erythematosis and scleroderma with CTLA4-Ig and the use of CTLA4-Ig in combination with other immunosuppressants...More specific claims cover methods for stable gene delivery to lymphocytes, dendritic cells and hematopoietic stem cells

The patent, which will remain in force until 2020, also covers a method of treating multiple sclerosis, systemic lupus erythematosis and scleroderma with CTLA4-Ig and the use of CTLA4-Ig in combination with other immunosuppressants

The patent application covers methods for synthesizing covalently linked galactose to existing cancer drugs, and methods for treating cancer patients to reduce toxicity while improving antitumor activity

The patent application covers methods for synthesizing covalently linked galactose to existing cancer drugs, and methods for treating cancer patients to reduce toxicity while improving antitumor activity

Exclusively licensed to Peregrine, the patent covers methods for selectively delivering liposomes to tumors that act to increase vascular permeability and expand blood volume at or in proximity to the tumor site